ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GPL Graft Polymer (uk) Plc

0.175
-0.05 (-22.22%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Graft Polymer (uk) Plc LSE:GPL London Ordinary Share GB00BMD1Z199 ORD GBP0.001
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.05 -22.22% 0.175 0.15 0.20 0.225 0.175 0.225 1,070,100 13:37:18
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Business Services, Nec 542k -2.71M -0.0260 -0.07 176.97k

Graft Polymer (UK) PLC Notice of AGM (2616R)

04/07/2022 4:50pm

UK Regulatory


Graft Polymer (uk) (LSE:GPL)
Historical Stock Chart


From Mar 2022 to Mar 2024

Click Here for more Graft Polymer (uk) Charts.

TIDMGPL

RNS Number : 2616R

Graft Polymer (UK) PLC

04 July 2022

4 July 2022

Graft Polymer (UK) Plc

("Graft Polymer", the "Company", and together with its subsidiaries, the "Group")

Notice of Annual General Meeting

Graft Polymer (UK) Plc (LSE: GPL), a business focused on the development and commercial production of polymer modification, biological supplements, and nano-drug delivery systems, announces that its Annual General Meeting ("AGM") will be held at the offices of Memery Crystal LLP, 165 Fleet Street, London EC4A 2DY on 28 July 2022 at 10am.

Notice of AGM and a Form of Proxy have been sent to the shareholders of the Company. The notice of AGM is also available on the Company's website https://graftpolymer.com/

**ENDS**

For more information, please visit https://www.graftpolymer.com or contact:

 
Graft Polymer (UK) Plc             via Tavistock 
Roby Zomer, Chairman 
Yifat Steuer, CFO 
 
Turner Pope Investments (Broker)   +44 20 3657 0050 
James Pope 
Andy Thacker 
 
Tavistock (Public Relations)       +44 207 920 3150 
Heather Armstrong                  graftpolymer@tavistock.co.uk 
Katie Hopkins 
 

About Graft Polymer

Graft Polymer is a UK incorporated holding company with an innovative research and manufacturing facility, based in Slovenia. The core business of the Group comprises polymer modification and drug delivery systems developments. Established in 2017, the Group has already introduced more than 50 products to the market.

The Group has developed a proprietary set of polymer modification technologies, which can improve existing products and processing methodologies by enhancing performance, simplifying manufacturing, reducing material consumption, widening the choice of feedstocks, and reducing costs.

In particular, the Group's techniques allow the combination of otherwise incompatible polymers, facilitating the creation of polymer composites engineered at a molecular level, that combine the attractive properties of different input materials. This enables customers to receive a synergism of properties in polymer composites.

The solutions and products offered by the Group are designed to improve performance, reduce raw materials consumption, and enhance the physical characteristic values of finished products or improve or modify their chemical interaction. In the past several years, there has been increased emphasis by the industry as a whole on applications of grafted polymers, which are produced by monomers being covalently bonded and polymerised as side chains onto the main polymer chain (the backbone).

In 2020, the Group launched a new division named GraftBio to develop IP for Bio/Pharma applications. This includes a drug delivery system to support and provide solutions to the market, which had been heavily impacted by the COVID-19 pandemic. The GraftBio division has been granted HACCP certification for its production facility. The Group has developed a set of drug delivery platforms that enable it to licence its DDS platform (IP) to MGC Pharmaceuticals Limited ("MGC"; LSE: MXC) in relation to MGC's CimetrA(TM) and CannEpil-IL(TM) products. The Group expects to receive royalty payments resulting from the sale by MGC of CimetrA(TM) and CannEpil-IL(TM) products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAUSSVRUOUBRAR

(END) Dow Jones Newswires

July 04, 2022 11:50 ET (15:50 GMT)

1 Year Graft Polymer (uk) Chart

1 Year Graft Polymer (uk) Chart

1 Month Graft Polymer (uk) Chart

1 Month Graft Polymer (uk) Chart

Your Recent History

Delayed Upgrade Clock